JP2022506110A - 治療用化合物および組成物 - Google Patents

治療用化合物および組成物 Download PDF

Info

Publication number
JP2022506110A
JP2022506110A JP2021523278A JP2021523278A JP2022506110A JP 2022506110 A JP2022506110 A JP 2022506110A JP 2021523278 A JP2021523278 A JP 2021523278A JP 2021523278 A JP2021523278 A JP 2021523278A JP 2022506110 A JP2022506110 A JP 2022506110A
Authority
JP
Japan
Prior art keywords
compound
subject
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523278A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020092592A5 (https=
JP2022506110A5 (https=
Inventor
ニール ジェイ． ヘイワード，
バートランド エル． チェナード，
ユエリアン シュー，
ロベルタ エル． ドロウ，
マイケル イー． マティソン，
アレクサンダー コルチンスキ，
リチャード フォルニコラ，
Original Assignee
エクセセーラ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクセセーラ ファーマシューティカルズ インコーポレイテッド filed Critical エクセセーラ ファーマシューティカルズ インコーポレイテッド
Publication of JP2022506110A publication Critical patent/JP2022506110A/ja
Publication of JPWO2020092592A5 publication Critical patent/JPWO2020092592A5/ja
Publication of JP2022506110A5 publication Critical patent/JP2022506110A5/ja
Priority to JP2024185222A priority Critical patent/JP2025011310A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/04—Use of organic materials, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3672—Means preventing coagulation
    • A61M1/3673—Anticoagulant coating, e.g. Heparin coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021523278A 2018-10-30 2019-10-30 治療用化合物および組成物 Pending JP2022506110A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024185222A JP2025011310A (ja) 2018-10-30 2024-10-21 治療用化合物および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752503P 2018-10-30 2018-10-30
US62/752,503 2018-10-30
PCT/US2019/058896 WO2020092592A1 (en) 2018-10-30 2019-10-30 Therapeutic compounds and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024185222A Division JP2025011310A (ja) 2018-10-30 2024-10-21 治療用化合物および組成物

Publications (3)

Publication Number Publication Date
JP2022506110A true JP2022506110A (ja) 2022-01-17
JPWO2020092592A5 JPWO2020092592A5 (https=) 2022-10-28
JP2022506110A5 JP2022506110A5 (https=) 2022-10-28

Family

ID=70464752

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523278A Pending JP2022506110A (ja) 2018-10-30 2019-10-30 治療用化合物および組成物
JP2024185222A Pending JP2025011310A (ja) 2018-10-30 2024-10-21 治療用化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024185222A Pending JP2025011310A (ja) 2018-10-30 2024-10-21 治療用化合物および組成物

Country Status (10)

Country Link
US (1) US20210261524A1 (https=)
EP (1) EP3873444A4 (https=)
JP (2) JP2022506110A (https=)
KR (1) KR20210087467A (https=)
CN (1) CN112996495A (https=)
AU (1) AU2019373237A1 (https=)
BR (1) BR112021008345A2 (https=)
CA (1) CA3117470A1 (https=)
IL (1) IL282766A (https=)
WO (1) WO2020092592A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
EP3749662A4 (en) 2018-02-07 2021-07-14 Exithera Pharmaceuticals Inc. THERAPEUTIC COMPOUNDS AND COMPOSITIONS
KR20210084581A (ko) * 2018-10-30 2021-07-07 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
IL301410A (en) * 2020-09-17 2023-05-01 Exithera Pharmaceuticals Inc FACTOR XIa OR KALLIKREIN INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE THEREOF
CN116782911A (zh) * 2020-09-17 2023-09-19 艾克赛特赫拉制药有限责任公司 治疗性化合物、组合物及其使用方法
TW202346278A (zh) * 2022-03-28 2023-12-01 大陸商四川海思科製藥有限公司 2-氨基吡啶衍生物製備方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067203A1 (en) * 1998-06-22 1999-12-29 Astrazeneca Ab Novel compounds useful in pain management
US7501404B2 (en) * 2005-04-04 2009-03-10 Daimed Substituted azetidinones
JP2010523693A (ja) * 2007-04-10 2010-07-15 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なチアゾリル化合物
JP2014532070A (ja) * 2011-10-14 2014-12-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
JP2017507933A (ja) * 2014-02-07 2017-03-23 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物
WO2018118705A1 (en) * 2016-12-23 2018-06-28 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067203A1 (en) * 1998-06-22 1999-12-29 Astrazeneca Ab Novel compounds useful in pain management
US7501404B2 (en) * 2005-04-04 2009-03-10 Daimed Substituted azetidinones
JP2010523693A (ja) * 2007-04-10 2010-07-15 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なチアゾリル化合物
JP2014532070A (ja) * 2011-10-14 2014-12-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
JP2017507933A (ja) * 2014-02-07 2017-03-23 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物
WO2018118705A1 (en) * 2016-12-23 2018-06-28 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編, 最新 創薬化学 下巻, vol. p.347-365, JPN6014029314, 1999, ISSN: 0005188160 *
PHARM TECH JAPAN, vol. 18, no. 10, JPN7014002019, 2002, pages 81 - 96, ISSN: 0005188161 *
SIKORA, KAROL ET AL.: "Citropin 1.1 Trifluoroacetate to Chloride Counter-Ion Exchange in HCl-Saturated Organic Solutions: A", INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, vol. 24(2), JPN6023045153, 2018, pages 265 - 270, ISSN: 0005495109 *

Also Published As

Publication number Publication date
KR20210087467A (ko) 2021-07-12
CN112996495A (zh) 2021-06-18
JP2025011310A (ja) 2025-01-23
US20210261524A1 (en) 2021-08-26
EP3873444A1 (en) 2021-09-08
EP3873444A4 (en) 2022-08-10
IL282766A (en) 2021-06-30
BR112021008345A2 (pt) 2021-08-03
WO2020092592A1 (en) 2020-05-07
AU2019373237A1 (en) 2021-04-22
CA3117470A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP2022506110A (ja) 治療用化合物および組成物
US20230270731A1 (en) Therapeutic compounds and compositions
US20210253550A1 (en) Therapeutic compounds and compositions
US20190315711A1 (en) Therapeutic compounds and compositions
JP2024023490A (ja) 治療用化合物および組成物
RU2813780C2 (ru) Терапевтические соединения и композиции
CN116782911A (zh) 治疗性化合物、组合物及其使用方法
US20230218594A1 (en) Therapeutic compounds, compositions, and methods of use thereof
JPWO2020059812A1 (ja) ４−（｛（４ｓ）−１−（４−カルバムイミドイルベンゾイル）−４−［４−（メチルスルホニル）ピペラジン−１−イル］−ｌ−プロリル｝アミノ）安息香酸の新規塩およびその新規結晶形

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241029